Trials / Completed
CompletedNCT04309669
Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 167 (actual)
- Sponsor
- Laboratoire Innotech International · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess, in patients with moderate IDA, the Onset-of-Action of a daily treatment with Tot'Héma®. The onset of action is defined as the time required for a mean increase of at least 0,5g/dL from baseline in the haemoglobin level.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TOT'HEMA | three ampoules per day during 12 weeks |
Timeline
- Start date
- 2020-11-12
- Primary completion
- 2023-10-06
- Completion
- 2023-10-06
- First posted
- 2020-03-16
- Last updated
- 2023-10-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04309669. Inclusion in this directory is not an endorsement.